AEGIS CAPITAL CORP.OKYO Pharma LTD • February 22nd, 2023 • Biological products, (no disgnostic substances) • New York
The purpose of this placement agent agreement (the “Agreement”) is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “best efforts” basis in connection with the proposed secondary public offering (the “Placement”) by OKYO Pharma Limited (collectively, with its subsidiaries and affiliates, the “Company”) of its American depositary shares (the “Securities”). This Agreement sets forth certain conditions and assumptions upon which the Placement is premised. The Company confirms that entry into this Agreement and completion of the Placement with Aegis will not breach or otherwise violate the Company’s obligations to any other investment bank.
